​
​

SpringWorks Therapeutics (SWTX) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

SWTX Stock Forecast

SpringWorks Therapeutics stock forecast is as follows: an average price target of $67.33 (represents a 85.48% upside from SWTX’s last price of $36.30) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

SWTX Price Target

The average price target for SpringWorks Therapeutics (SWTX) is $67.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $76.00 to $50.00. This represents a potential 85.48% upside from SWTX's last price of $36.30.

SWTX Analyst Ratings

Buy

According to 3 Wall Street analysts, SpringWorks Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SWTX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

SpringWorks Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 08, 2024Robert BurnsH.C. Wainwright$76.00$33.93123.99%109.37%
Aug 09, 2022-H.C. Wainwright$94.00$39.66137.01%158.95%
May 27, 2022-Wedbush$50.00$18.72167.09%37.74%
May 24, 2022-Goldman Sachs$76.00$32.74132.13%109.37%
Row per page
Go to

The latest SpringWorks Therapeutics stock forecast, released on Aug 08, 2024 by Robert Burns from H.C. Wainwright, set a price target of $76.00, which represents a 123.99% increase from the stock price at the time of the forecast ($33.93), and a 109.37% increase from SWTX last price ($36.30).

SpringWorks Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$76.00
Last Closing Price$36.30$36.30$36.30
Upside/Downside-100.00%-100.00%109.37%

In the current month, the average price target of SpringWorks Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SpringWorks Therapeutics's last price of $36.30. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Aug 08, 2024H.C. WainwrightBuyBuyHold
Jun 18, 2022H.C. WainwrightBuyBuyHold
May 27, 2022WedbushOutperformOutperformHold
May 24, 2022Goldman SachsBuyBuyHold
Row per page
Go to

SpringWorks Therapeutics's last stock rating was published by H.C. Wainwright on Aug 08, 2024. The company gave SWTX a "Buy" rating, the same as its previous rate.

SpringWorks Therapeutics Financial Forecast

SpringWorks Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22Mar 21Dec 20
Revenue--------$5.45M--$35.00M
Avg Forecast$117.19M$99.09M$85.52M$71.80M$61.01M$53.28M$34.42M$12.07M$860.19K$3.82M$180.00$21.00M
High Forecast$128.90M$109.00M$94.07M$82.79M$66.83M$53.43M$34.42M$12.07M$1.57M$4.59M$216.00$21.00M
Low Forecast$105.95M$89.60M$77.32M$64.14M$52.67M$53.14M$34.42M$12.07M$498.36K$3.06M$144.00$21.00M
# Analysts111454224171710
Surprise %--------6.33%--1.67%

SpringWorks Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $12.07M, with a low forecast of $12.07M, and a high forecast of $12.07M. SWTX's average Quarter revenue forecast represents a 121.56% increase compared to the company's last Quarter revenue of $5.45M (Dec 23).

SpringWorks Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22Mar 21Dec 20
# Analysts111454224171710
EBITDA--------$-97.92M$-61.36M$-29.68M$11.38M
Avg Forecast$-23.44M$-19.82M$-17.10M$-14.36M$-12.20M$-10.66M$-6.88M$-2.41M$-172.04K$-47.26B$-23.25M$-4.20M
High Forecast$-21.19M$-17.92M$-15.46M$-12.83M$-10.53M$-10.63M$-6.88M$-2.41M$-99.67K$-37.81B$-18.60M$-4.20M
Low Forecast$-25.78M$-21.80M$-18.81M$-16.56M$-13.37M$-10.69M$-6.88M$-2.41M$-314.04K$-56.71B$-27.90M$-4.20M
Surprise %--------569.21%0.00%1.28%-2.71%

17 analysts predict SWTX's average Quarter EBITDA for Mar 21 to be $-23.25M, with a high of $-18.60M and a low of $-27.90M. This is -304.29% lower than SpringWorks Therapeutics's previous annual EBITDA (Dec 20) of $11.38M.

SpringWorks Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22Mar 21Dec 20
# Analysts111454224171710
Net Income--------$-94.32M$-62.13M$-29.79M$11.27M
Avg Forecast$-18.96M$-30.14M$-41.08M$-47.65M$-49.55M$-55.97M$-82.89M$-87.03M$-91.84M$-47.26B$-23.36M$-6.18M
High Forecast$-16.60M$-26.38M$-35.96M$-36.15M$-42.37M$-49.00M$-72.56M$-76.18M$-87.43M$-37.81B$-18.69M$-6.18M
Low Forecast$-21.42M$-34.05M$-46.41M$-61.62M$-56.01M$-63.24M$-93.66M$-98.34M$-98.45M$-56.71B$-28.03M$-6.18M
Surprise %--------1.03%0.00%1.28%-1.82%

SpringWorks Therapeutics's average Quarter net income forecast for Mar 21 is $-23.36M, with a range of $-28.03M to $-18.69M. SWTX's average Quarter net income forecast represents a -307.26% decrease compared to the company's last Quarter net income of $11.27M (Dec 20).

SpringWorks Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22Mar 21Dec 20
# Analysts111454224171710
SG&A--------$59.84M$27.37M$12.38M$8.52M
Avg Forecast$1.43B$1.21B$1.04B$875.94M$744.37M$650.03M$419.89M$147.23M$10.49M$46.65M$2.19K$256.19M
High Forecast$1.57B$1.33B$1.15B$1.01B$815.28M$651.78M$419.89M$147.24M$19.16M$55.98M$2.63K$256.19M
Low Forecast$1.29B$1.09B$943.34M$782.53M$642.58M$648.29M$419.89M$147.23M$6.08M$37.32M$1.76K$256.19M
Surprise %--------5.70%0.59%5640.55%0.03%

SpringWorks Therapeutics's average Quarter SG&A projection for Mar 24 is $147.23M, based on 2 Wall Street analysts, with a range of $147.23M to $147.24M. The forecast indicates a 146.06% rise compared to SWTX last annual SG&A of $59.84M (Dec 23).

SpringWorks Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Mar 22Mar 21Dec 20
# Analysts111454224171710
EPS---------$-1.27$-0.62$0.26
Avg Forecast$-0.26$-0.41$-0.55$-0.64$-0.67$-0.75$-1.12$-1.17$-1.24$-1.02$-0.51$-0.08
High Forecast$-0.22$-0.36$-0.48$-0.49$-0.57$-0.66$-0.98$-1.03$-1.18$-1.02$-0.51$-0.08
Low Forecast$-0.29$-0.46$-0.62$-0.83$-0.75$-0.85$-1.26$-1.32$-1.33$-1.02$-0.51$-0.08
Surprise %---------1.24%1.22%-3.12%

According to 17 Wall Street analysts, SpringWorks Therapeutics's projected average Quarter EPS for Mar 21 is $-0.51, with a low estimate of $-0.51 and a high estimate of $-0.51. This represents a -296.15% decrease compared to SWTX previous annual EPS of $0.26 (Dec 20).

SpringWorks Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.54$6.001011.11%Buy
BDTXBlack Diamond Therapeutics$2.43$14.75507.00%Buy
RLAYRelay Therapeutics$4.64$19.40318.10%Buy
SANASana Bio$2.35$8.00240.43%Buy
PLRXPliant Therapeutics$12.85$39.71209.03%Buy
DAWNDay One Biopharmaceuticals$13.34$38.80190.85%Buy
ARVNArvinas$25.11$71.00182.76%Buy
STOKStoke Therapeutics$11.27$30.60171.52%Buy
APLSApellis Pharmaceuticals$27.75$74.50168.47%Buy
TERNTerns Pharmaceuticals$5.71$14.25149.56%Buy
SWTXSpringWorks Therapeutics$36.30$67.3385.48%Buy
AMLXAmylyx Pharmaceuticals$5.19$6.6728.52%Buy
RNAAvidity Biosciences$42.56$54.5028.05%Buy
KYMRKymera Therapeutics$43.51$51.5018.36%Buy
BPMCBlueprint Medicines$96.62$109.7113.55%Buy
RVMDRevolution Medicines, Inc. Warrant$56.78$60.636.78%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

SWTX Forecast FAQ

Is SpringWorks Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, SpringWorks Therapeutics (SWTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SWTX's total ratings.

What is SWTX's price target?

SpringWorks Therapeutics (SWTX) average price target is $67.33 with a range of $50 to $76, implying a 85.48% from its last price of $36.3. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will SpringWorks Therapeutics stock go up soon?

According to Wall Street analysts' prediction for SWTX stock, the company can go up by 85.48% (from the last price of $36.3 to the average price target of $67.33), up by 109.37% based on the highest stock price target, and up by 37.74% based on the lowest stock price target.

Can SpringWorks Therapeutics stock reach $50?

SWTX's average twelve months analyst stock price target of $67.33 supports the claim that SpringWorks Therapeutics can reach $50 in the near future.

What are SpringWorks Therapeutics's analysts' financial forecasts?

SpringWorks Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $160.78M (high $166.74M, low $152.3M), average EBITDA is $-32.157M (high $-30.459M, low $-33.348M), average net income is $-275M (high $-240M, low $-311M), average SG&A $1.96B (high $2.03B, low $1.86B), and average EPS is $-3.709 (high $-3.233, low $-4.191). SWTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $373.6M (high $414.76M, low $337.02M), average EBITDA is $-74.72M (high $-67.403M, low $-82.951M), average net income is $-138M (high $-115M, low $-164M), average SG&A $4.56B (high $5.06B, low $4.11B), and average EPS is $-1.856 (high $-1.55, low $-2.202).

Did the SWTX's actual financial results beat the analysts' financial forecasts?

Based on SpringWorks Therapeutics's last annual report (Dec 2023), the company's revenue was $5.45M, beating the average analysts forecast of $860.19K by 533.23%. Apple's EBITDA was $-343M, beating the average prediction of $-172K by 199283.27%. The company's net income was $-325M, beating the average estimation of $-91.841M by 253.98%. Apple's SG&A was $197.55M, beating the average forecast of $10.49M by 1782.50%. Lastly, the company's EPS was $-0.0052, missing the average prediction of $-1.237 by -99.58%. In terms of the last quarterly report (Dec 2023), SpringWorks Therapeutics's revenue was $5.45M, beating the average analysts' forecast of $860.19K by 533.23%. The company's EBITDA was $-97.925M, beating the average prediction of $-172K by 56820.89%. SpringWorks Therapeutics's net income was $-94.322M, beating the average estimation of $-91.841M by 2.70%. The company's SG&A was $59.84M, beating the average forecast of $10.49M by 470.19%. Lastly, the company's EPS was $0, missing the average prediction of $-1.237 by -100.00%